Patents by Inventor Ellen James

Ellen James has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12251371
    Abstract: The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I?) is also provided.
    Type: Grant
    Filed: February 2, 2023
    Date of Patent: March 18, 2025
    Assignee: Cybin UK Ltd.
    Inventors: Peter Rands, Ellen James, Tiffanie Benway, Zelah Joel, Marie Layzell
  • Publication number: 20250032450
    Abstract: The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, with a pH from 5 to 6.5, preferably from about 5 to about 6, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg/ml or greater as the freebase equivalent. These formulations can comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less. Such formulations are surprisingly suitable both for intramuscular injection and nebulised inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.
    Type: Application
    Filed: November 18, 2022
    Publication date: January 30, 2025
    Inventors: Peter RANDS, Carol ROUTLEDGE, Marie LAYZELL, Ellen JAMES, Zelah JOEL, Tiffanie BENWAY, Meghan GOOD
  • Publication number: 20240342101
    Abstract: The present invention relates to a solid dosage form comprising two or more compounds selected from N,N-dimethyltryptamine and its deuterated analogues and pharmaceutically acceptable salts thereof, and methods of treatment (e.g., of a psychiatric disorder or a neurological disorder) comprising administering the solid dosage form to a patient in need thereof.
    Type: Application
    Filed: June 20, 2024
    Publication date: October 17, 2024
    Applicant: Cybin UK Ltd
    Inventors: Peter RANDS, Tiffanie BENWAY, Zelah JOEL, Marie LAYZELL, Ellen JAMES
  • Publication number: 20240325351
    Abstract: The invention relates to a combination, combination for use, method for treating, kit, dosage regime, delivery device, method of adjuvant treatment, short-duration psychedelic agent for use, or parenteral formulation for use in the treatment of a psychiatric disorder in a patient. In particular, the invention relates to the administration of a short-duration psychedelic agent in combination with a monoamine antidepressant, such as a selective serotonin reuptake inhibitor (SSRI).
    Type: Application
    Filed: March 28, 2024
    Publication date: October 3, 2024
    Applicant: Cybin UK Ltd.
    Inventors: Peter RANDS, Carol ROUTLEDGE, Ellen JAMES, Tiffanie BENWAY, Zelah JOEL, Victoria ATTWOOLL, Meghan GOOD
  • Patent number: 12042564
    Abstract: The present invention relates to a solid dosage form comprising two or more compounds selected from N,N-dimethyltryptamine and its deuterated analogues and pharmaceutically acceptable salts thereof, and methods of treatment (e.g., of a psychiatric disorder or a neurological disorder) comprising administering the solid dosage form to a patient in need thereof.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: July 23, 2024
    Assignee: CYBIN UK LTD
    Inventors: Peter Rands, Tiffanie Benway, Zelah Joel, Marie Layzell, Ellen James
  • Publication number: 20240016782
    Abstract: The present invention relates to inhalable formulations, and kits and methods suitable for the preparation of such inhalable formulations. The inhalable formulations comprise a freebase of a deuterium-substituted dimethyltryptamine compound. The inhalable formulations also comprise a biocompatible excipient. Such formulations are suitable for inhalation and have uses in the treatment of psychiatric or neurological disorders. Deuterium-substituted dimethyltryptamine compounds may be metabolised more slowly than their protio analogues, allowing for a longer lasting therapeutic effect.
    Type: Application
    Filed: December 1, 2021
    Publication date: January 18, 2024
    Inventors: Peter RANDS, Ellen JAMES, Tiffanie BENWAY, Zelah JOEL, Marie LAYZELL
  • Patent number: 11773062
    Abstract: Described herein are compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I?) is also provided.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: October 3, 2023
    Assignee: Small Pharma Ltd
    Inventors: Peter Rands, Ellen James, Tiffanie Benway
  • Publication number: 20230181530
    Abstract: The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I?) is also provided.
    Type: Application
    Filed: February 2, 2023
    Publication date: June 15, 2023
    Applicant: Small Pharma Ltd.
    Inventors: Peter RANDS, Ellen JAMES, Tiffanie BENWAY, Zelah JOEL, Marie LAYZELL
  • Patent number: 11660289
    Abstract: The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I?) is also provided.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: May 30, 2023
    Assignee: SMALL PHARMA LTD.
    Inventors: Peter Rands, Ellen James, Tiffanie Benway, Zelah Joel, Marie Layzell
  • Publication number: 20230149293
    Abstract: The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, with a pH from 5 to 6.5, preferably from about 5 to about 6, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg/ml or greater as the freebase equivalent. These formulations can comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less. Such formulations are surprisingly suitable both for intramuscular injection and nebulised inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.
    Type: Application
    Filed: November 18, 2022
    Publication date: May 18, 2023
    Inventors: Peter RANDS, Carol ROUTLEDGE, Marie LAYZELL, Ellen JAMES, Zelah JOEL, Tiffanie BENWAY, Meghan GOOD
  • Patent number: 11471417
    Abstract: Compounds, compositions, methods, and uses are described for therapeutic deuterated N,N-dimethyltryptamine compounds (e.g., a single compound or a plurality of deuterated N,N-dimethyltryptamine compounds) such as N,N-dimethyltryptamine compounds, ?-protio, ?-deutero-N,N-dimethyltryptamine compounds, ?,?-dideutero-N,N-dimethyltryptamine compounds, and pharmaceutically acceptable salts of these compounds. The deuterated N,N-dimethyltryptamine compound may have an increased half-life compared with the half-life of undeuterated N,N-dimethyltryptamine. For example, a deuterated N,N-dimethyltryptamine compound may be used in therapy and have a Formula (I): wherein: the ratio of deuterium:protium in the compound is greater than that found naturally in hydrogen; each R1 is independently selected from H and D; R2 is selected from CH3 and CD3; R3 is selected from CH3 and CD3; each yH is independently selected from H and D, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: October 18, 2022
    Assignee: Small Pharma Ltd
    Inventors: Peter Rands, Tiffanie Benway, Zelah Joel, Marie Layzell, Ellen James
  • Publication number: 20220202775
    Abstract: The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I?) is also provided.
    Type: Application
    Filed: February 25, 2022
    Publication date: June 30, 2022
    Applicant: Small Pharma Ltd
    Inventors: Peter Rands, Ellen James, Tiffanie Benway, Zelah Joel, Marie Layzell
  • Publication number: 20220169606
    Abstract: The present invention relates to compositions comprising compounds of formula I and II. These compositions have uses in the treatment of psychiatric or neurological disorders. Varying the relative amounts of the compounds of formula I and II within the compositions is expected to modulate the therapeutic effect. Related compounds of formula Ill comprise d3-monomethylamino or d6-dimethylamino groups and are useful internal standards for quantifying the amount of a target compound, such as an analogous compound comprising protio-monomethylamino or protio-dimethylamino groups. Thus, the present invention also relates to compounds of formula Ill and their uses as internal standards in assays for quantifying the amount of a target compound in a sample. A method of quantifying the amount of a target compound in a sample by adding a known amount of a compound of formula Ill to the sample is also included.
    Type: Application
    Filed: December 1, 2020
    Publication date: June 2, 2022
    Applicant: Small Pharma Ltd.
    Inventors: Peter Rands, Ellen James, Tiffanie Benway
  • Publication number: 20220081396
    Abstract: Described herein are compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I?) is also provided.
    Type: Application
    Filed: March 22, 2021
    Publication date: March 17, 2022
    Applicant: Small Pharma Ltd.
    Inventors: Peter Rands, Ellen James, Tiffanie Benway
  • Publication number: 20210403426
    Abstract: Compounds, compositions, methods, and uses are described for therapeutic deuterated N,N-dimethyltryptamine compounds (e.g., a single compound or a plurality of deuterated N,N-dimethyltryptamine compounds) such as N,N-dimethyltryptamine compounds, ?-protio, ?-deutero-N,N-dimethyltryptamine compounds, ?,?-dideutero-N,N-dimethyltryptamine compounds, and pharmaceutically acceptable salts of these compounds. The deuterated N,N-dimethyltryptamine compound may have an increased half-life compared with the half-life of undeuterated N,N-dimethyltryptamine. For example, a deuterated N,N-dimethyltryptamine compound may be used in therapy and have a Formula (I): wherein: the ratio of deuterium:protium in the compound is greater than that found naturally in hydrogen; each R1 is independently selected from H and D; R2 is selected from CH3 and CD3; R3 is selected from CH3 and CD3; each yH is independently selected from H and D, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 26, 2021
    Publication date: December 30, 2021
    Applicant: Small Pharma Ltd
    Inventors: Peter Rands, Tiffanie Benway, Zelah Joel, Marie Layzell, Ellen James
  • Publication number: 20210378969
    Abstract: The present invention relates to a solid dosage form comprising two or more compounds selected from N,N-dimethyltryptamine and its deuterated analogues and pharmaceutically acceptable salts thereof, and methods of treatment (e.g., of a psychiatric disorder or a neurological disorder) comprising administering the solid dosage form to a patient in need thereof.
    Type: Application
    Filed: May 13, 2021
    Publication date: December 9, 2021
    Applicant: Small Pharma Ltd.
    Inventors: Peter Rands, Tiffanie Benway, Zelah Joel, Marie Layzell, Ellen James
  • Publication number: 20210315840
    Abstract: This invention relates to high concentration solid oral dosage forms of a ketamine metabolite selected from 2R,6R-hydroxynorketamine, 2S,6S-hydroxynorketamine, R-5,6-dehydronorketamine and S-5,6-dehydronorketamine.
    Type: Application
    Filed: September 25, 2018
    Publication date: October 14, 2021
    Applicant: SMALL PHARMA LTD
    Inventors: Trevor ROBBINS, Benjamin PHILLIPS, David PEARSON, Lorraine SHARP, Richard MYERSON, Peter RANDS, Marie LAYZELL, Zelab JOEL, Tiffanie BENWAY, Ellen JAMES
  • Patent number: 6768285
    Abstract: Manipulation and regulation of power provided by a time-varying power source to continuously provide power to a load by insuring that any minimum voltage or current requirements of the load are met even when the power provided by the time-varying power source itself does not satisfy the load's minimum voltage or current requirements. For a load having a minimum voltage requirement, power from a time varying source will be boosted as necessary to insure that the minimum voltage is maintained.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: July 27, 2004
    Inventor: Ellen James
  • Patent number: 6600292
    Abstract: A power controller which includes a boost pre-regulator receiving power from a power source providing an input voltage and an input current, and having compensation networks which are dynamically adjusted for power level, the pre-regulator providing power factor correction to maintain a total harmonic distortion of the input current of 2-3% at full power, and less than 5% at all power levels, while the input voltage is anywhere within the range of 95 to 265 VAC; and a forward converter receiving control from a current-mode controller which is in turn under the control of the boost pre-regulator, in order to achieve substantially constant duty cycle of the forward converter over the entire range of power levels.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: July 29, 2003
    Inventor: Ellen James
  • Publication number: 20030071597
    Abstract: Manipulation and regulation of power provided by a time-varying power source to continuously provide power to a load by insuring that any minimum voltage or current requirements of the load are met even when the power provided by the time-varying power source itself does not satisfy the load's minimum voltage or current requirements. For a load having a minimum voltage requirement, power from a time varying source will be boosted as necessary to insure that the minimum voltage is maintained.
    Type: Application
    Filed: July 22, 2002
    Publication date: April 17, 2003
    Inventor: Ellen James